MedTrace Logo

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

NCT07002320 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-04-15

No results posted yet for this study

Summary

ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

SX-682

SX-682 is supplied as 100mg film coated tablets.

DRUG

Apalutamide

Apalutamide is supplied as 60mg film coated tablets.

Sponsors & Collaborators

  • Prostate Cancer UK

    collaborator OTHER

  • Janssen Pharmaceutica N.V., Belgium

    collaborator INDUSTRY

  • Oncology Institute of Southern Switzerland

    collaborator OTHER

  • Syntrix Biosystems, Inc.

    collaborator INDUSTRY

  • Royal Marsden NHS Foundation Trust

    collaborator OTHER

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • Belfast Health and Social Care Trust

    collaborator OTHER

  • Institute of Oncology Research (IOR)

    collaborator UNKNOWN

  • Institute of Cancer Research, United Kingdom

    lead OTHER

Principal Investigators

  • Professor Johann de Bono, MB ChB, FRCP, MSc, PhD, FMedSc · Institute of Cancer Research, United Kingdom

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2029-10-31
Completion
2029-10-31

Countries

  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07002320 on ClinicalTrials.gov